In melanoma cells, targeted therapy induced AXL expression, and co-treatment of AXL-expressing cells with an antibody–drug conjugate and MAPK inhibitors synergistically prevented tumor growth in melanoma patient-derived xenografts [80]. Here, AXL is linked to melanoma.